Intellipharmaceutics International Inc.

OTCPK:IPCI.Q Stock Report

Market Cap: US$1.8m

Intellipharmaceutics International Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Isa Odidi

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure26.9yrs
CEO ownershipn/a
Management average tenure26.9yrs
Board average tenure18.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Isa Odidi's remuneration changed compared to Intellipharmaceutics International's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2023n/an/a

-US$3m

May 31 2023n/an/a

-US$2m

Feb 28 2023n/an/a

-US$2m

Nov 30 2022US$348kUS$335k

-US$3m

Aug 31 2022n/an/a

-US$4m

May 31 2022n/an/a

-US$5m

Feb 28 2022n/an/a

-US$5m

Nov 30 2021US$375kUS$361k

-US$5m

Aug 31 2021n/an/a

-US$5m

May 31 2021n/an/a

-US$3m

Feb 28 2021n/an/a

-US$3m

Nov 30 2020US$363kUS$349k

-US$3m

Aug 31 2020n/an/a

-US$3m

May 31 2020n/an/a

-US$6m

Feb 29 2020n/an/a

-US$7m

Nov 30 2019US$560kUS$340k

-US$8m

Aug 31 2019n/an/a

-US$11m

May 31 2019n/an/a

-US$13m

Feb 28 2019n/an/a

-US$14m

Nov 30 2018US$1mUS$350k

-US$14m

Compensation vs Market: Insufficient data to establish whether Isa's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Isa's compensation has been consistent with company performance over the past year.


CEO

Isa Odidi (66 yo)

26.9yrs

Tenure

US$347,941

Compensation

Dr. Isa Odidi, Ph D., MBA has been the Chief Executive Officer and Co-Chief Scientific Officer at IntelliPharmaCeutics International Inc. since September 1, 2004. In 1998, Dr. Odidi co-founded Intellipharm...


Leadership Team

NamePositionTenureCompensationOwnership
Isa Odidi
Co-Founder26.9yrsUS$347.94kno data
Amina Odidi
President26.9yrsUS$347.94kno data
Patrick Yat
Vice-President of Chemistry & Analytical Services19.9yrsUS$119.93k0.0082%
$ 151.4
Fazayill Shaideen
Controllerno datano datano data

26.9yrs

Average Tenure

66yo

Average Age

Experienced Management: IPCI.Q's management team is seasoned and experienced (26.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Isa Odidi
Co-Founder20.3yrsUS$347.94kno data
Amina Odidi
President20.3yrsUS$347.94kno data
Bahadur Madhani
Independent Director18.8yrsUS$34.94k0.0023%
$ 41.9
Shawn Graham
Independent Non-Executive Director6.6yrsUS$31.22kno data
Norman Betts
Independent Non-Executive Director5.9yrsUS$31.22kno data

18.8yrs

Average Tenure

65yo

Average Age

Experienced Board: IPCI.Q's board of directors are seasoned and experienced ( 18.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:11
End of Day Share Price 2024/12/19 00:00
Earnings2023/08/31
Annual Earnings2022/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Intellipharmaceutics International Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Raymond DeaconBrean Capital
Jonathan AschoffBrean Capital